Oppenheimer raised the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $19 and keeps an Outperform rating on the shares following quarterly results and business update highlighting launch progress for Zevaskyn, after the FDA approval in April. Q2 ending cash was bolstered by the sale of Abeona’s PRV during the quarter for $155M, ending Q2 with $226M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics Reports Strong Financial Turnaround
- Abeona Therapeutics reports Q2 EPS ($1.71) vs (26c) last year
- Abeona Therapeutics expects cash to fund operations for over two years
- Abeona Therapeutics announces employee inducement grants
- AscellaHealth highlights value of HUB partnership with Abeona Therapeutics